Evidence map›Paper›PMID 19781968›Full record

ArticleMolecular genetics and metabolism2010

Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting.

Michelle Cook Sangar, Hindupur K Anandatheerthavarada, Martha V Martin, F Peter Guengerich, Narayan G Avadhani

Open access · greenAbstract read
In one paragraph

Article in Molecular genetics and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michelle Cook SangarDept. of Animal Biology and the Mari Lowe Center for Comparative Oncology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hindupur K Anandatheerthavarada
Martha V Martin
F Peter Guengerich
Narayan G Avadhani
University of Pennsylvania · USVanderbilt University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007170 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BRASS, LAWRENCE F · 1985 to 2022
$54.0M
Role of Mitochondria-Targeted CYP2D6 in Chemical ToxicityR01GM034883 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI AVADHANI, NARAYAN G · 1985 to 2018
$6.1M
Metabolism of Carcinogens and Drugs by Human P450sR37CA090426 · NCI · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2006 to 2015
$3.6M
Role of Mitochondria Targeted CYP2E1 and HO-1 in Alcohol Mediated Tissue InjuryR01AA017749 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI AVADHANI, NARAYAN G · 2008 to 2012
$1.8M
NCI NIH HHS R37 CA090426NIAAA NIH HHS R01 AA017749NIGMS NIH HHS R01 GM034883NIGMS NIH HHS T32 GM007170
6 · The paper itself

Abstract

Human cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of approximately 20% of drugs in common clinical use. The CYP2D6 gene locus is highly polymorphic. Many of the polymorphisms have been shown to be clinically relevant and can account for inter-individual differences in the metabolism of specific drugs. In addition to the established sources of variability in CYP2D6-dependent drug metabolism, a recent study in our laboratory identified CYP2D6 in the mitochondria of human liver samples and found that it is metabolically active in this novel location. In the present study we show that mutations are present in the targeting signal region of CYP2D6 that may help to account for the inter-individual variability that was observed previously in the level of the mitochondrial enzyme in human liver samples. These mutations were identified within the ER targeting domain, the proline-rich domain as well as the putative protein kinase A (PKA) and protein kinase C (PKC)-specific phosphorylation sites. In vitro studies demonstrate that the mutations identified in the targeting signals affect the efficiency of mitochondrial targeting of CYP2D6. Since the mitochondrial enzyme has been shown to be active in drug metabolism, this pharmacogenetic variation could play a role in modulating the response of an individual to drug therapy.

Indexed as

MutationAlternative SplicingAmino Acid SequenceAnimalsCytochrome P-450 CYP2D6ExonsGenetic VariationHumansLiverMicrosomesMitochondria, LiverMitochondrial ProteinsMolecular Sequence DataProtein Sorting SignalsProtein TransportRatsCytochrome P-450 CYP2D6Mitochondrial ProteinsProtein Sorting Signals

Identifiers

PMID19781968
PMCPMC2794965
OpenAlexW2107864670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.